These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22929303)

  • 1. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models.
    Ogura Y; Ouchi N; Ohashi K; Shibata R; Kataoka Y; Kambara T; Kito T; Maruyama S; Yuasa D; Matsuo K; Enomoto T; Uemura Y; Miyabe M; Ishii M; Yamamoto T; Shimizu Y; Walsh K; Murohara T
    Circulation; 2012 Oct; 126(14):1728-38. PubMed ID: 22929303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart.
    Oshima Y; Ouchi N; Sato K; Izumiya Y; Pimentel DR; Walsh K
    Circulation; 2008 Jun; 117(24):3099-108. PubMed ID: 18519848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism.
    Ouchi N; Oshima Y; Ohashi K; Higuchi A; Ikegami C; Izumiya Y; Walsh K
    J Biol Chem; 2008 Nov; 283(47):32802-11. PubMed ID: 18718903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal nephrectomy model.
    Hayakawa S; Ohashi K; Shibata R; Kataoka Y; Miyabe M; Enomoto T; Joki Y; Shimizu Y; Kambara T; Uemura Y; Yuasa D; Ogawa H; Matsuo K; Hiramatsu-Ito M; van den Hoff MJ; Walsh K; Murohara T; Ouchi N
    J Am Soc Nephrol; 2015 Mar; 26(3):636-46. PubMed ID: 25071081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-29a in mesenchymal stem cells inhibits FSTL1 secretion and promotes cardiac myocyte apoptosis in hypoxia-reoxygenation injury.
    Li KS; Jiang WP; Li QC; Zhang HW; Bai Y; Zhang X; Li HY
    Cardiovasc Pathol; 2020; 46():107180. PubMed ID: 31945680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Follistatin-like 1-engineered mesenchymal stem cells prevent myocardial ischemic reperfusion injury].
    Zhang MQ; Chen H; Zhai CL; Tu JF; Shen Y; Pang LX; Xu QR
    Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(25):2017-22. PubMed ID: 27470962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury.
    Miyabe M; Ohashi K; Shibata R; Uemura Y; Ogura Y; Yuasa D; Kambara T; Kataoka Y; Yamamoto T; Matsuo K; Joki Y; Enomoto T; Hayakawa S; Hiramatsu-Ito M; Ito M; Van Den Hoff MJ; Walsh K; Murohara T; Ouchi N
    Cardiovasc Res; 2014 Jul; 103(1):111-20. PubMed ID: 24743592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway.
    Jin YK; Li XH; Wang W; Liu J; Zhang W; Fang YS; Zhang ZF; Dai HP; Ning W; Wang C
    Chin Med J (Engl); 2018 Aug; 131(16):1917-1925. PubMed ID: 30082522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism.
    Kambara T; Ohashi K; Shibata R; Ogura Y; Maruyama S; Enomoto T; Uemura Y; Shimizu Y; Yuasa D; Matsuo K; Miyabe M; Kataoka Y; Murohara T; Ouchi N
    J Biol Chem; 2012 Jun; 287(23):18965-73. PubMed ID: 22514273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms.
    Kataoka Y; Shibata R; Ohashi K; Kambara T; Enomoto T; Uemura Y; Ogura Y; Yuasa D; Matsuo K; Nagata T; Oba T; Yasukawa H; Numaguchi Y; Sone T; Murohara T; Ouchi N
    J Am Coll Cardiol; 2014 Jun; 63(24):2722-33. PubMed ID: 24768874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture.
    Maruyama S; Nakamura K; Papanicolaou KN; Sano S; Shimizu I; Asaumi Y; van den Hoff MJ; Ouchi N; Recchia FA; Walsh K
    EMBO Mol Med; 2016 Aug; 8(8):949-66. PubMed ID: 27234440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C1q/TNF-related protein-1 functions to protect against acute ischemic injury in the heart.
    Yuasa D; Ohashi K; Shibata R; Mizutani N; Kataoka Y; Kambara T; Uemura Y; Matsuo K; Kanemura N; Hayakawa S; Hiramatsu-Ito M; Ito M; Ogawa H; Murate T; Murohara T; Ouchi N
    FASEB J; 2016 Mar; 30(3):1065-75. PubMed ID: 26578687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myonectin Is an Exercise-Induced Myokine That Protects the Heart From Ischemia-Reperfusion Injury.
    Otaka N; Shibata R; Ohashi K; Uemura Y; Kambara T; Enomoto T; Ogawa H; Ito M; Kawanishi H; Maruyama S; Joki Y; Fujikawa Y; Narita S; Unno K; Kawamoto Y; Murate T; Murohara T; Ouchi N
    Circ Res; 2018 Dec; 123(12):1326-1338. PubMed ID: 30566056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and Chronic Increases of Circulating FSTL1 Normalize Energy Substrate Metabolism in Pacing-Induced Heart Failure.
    Seki M; Powers JC; Maruyama S; Zuriaga MA; Wu CL; Kurishima C; Kim L; Johnson J; Poidomani A; Wang T; Muñoz E; Rajan S; Park JY; Walsh K; Recchia FA
    Circ Heart Fail; 2018 Jan; 11(1):e004486. PubMed ID: 29317401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome.
    Widera C; Giannitsis E; Kempf T; Korf-Klingebiel M; Fiedler B; Sharma S; Katus HA; Asaumi Y; Shimano M; Walsh K; Wollert KC
    Clin Chem; 2012 Aug; 58(8):1233-41. PubMed ID: 22675198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload.
    Shimano M; Ouchi N; Nakamura K; van Wijk B; Ohashi K; Asaumi Y; Higuchi A; Pimentel DR; Sam F; Murohara T; van den Hoff MJ; Walsh K
    Proc Natl Acad Sci U S A; 2011 Oct; 108(43):E899-906. PubMed ID: 21987816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury.
    Oshima Y; Ouchi N; Shimano M; Pimentel DR; Papanicolaou KN; Panse KD; Tsuchida K; Lara-Pezzi E; Lee SJ; Walsh K
    Circulation; 2009 Oct; 120(16):1606-15. PubMed ID: 19805648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follistatin-Like 1 Attenuates Ischemia/Reperfusion Injury in Cardiomyocytes via Regulation of Autophagy.
    Yang W; Duan Q; Zhu X; Tao K; Dong A
    Biomed Res Int; 2019; 2019():9537382. PubMed ID: 31139662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.
    Bao W; Hu E; Tao L; Boyce R; Mirabile R; Thudium DT; Ma XL; Willette RN; Yue TL
    Cardiovasc Res; 2004 Feb; 61(3):548-58. PubMed ID: 14962485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cGMP-Elevating Compounds and Ischemic Conditioning Provide Cardioprotection Against Ischemia and Reperfusion Injury via Cardiomyocyte-Specific BK Channels.
    Frankenreiter S; Bednarczyk P; Kniess A; Bork NI; Straubinger J; Koprowski P; Wrzosek A; Mohr E; Logan A; Murphy MP; Gawaz M; Krieg T; Szewczyk A; Nikolaev VO; Ruth P; Lukowski R
    Circulation; 2017 Dec; 136(24):2337-2355. PubMed ID: 29051185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.